APLS - Apellis falls as EU experts decline to back eye disorder therapy
2024-06-28 10:19:27 ET
More on Apellis Pharmaceuticals
- Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
- Apellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
- Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Call Transcript
- Apellis Pharma up on phase 2 data for kidney disease treatment pegcetacoplan
- Apellis stock sell-off over Syfovre sales "overdone," says Citi